Overexpression of microRNA-155 enhances the efficacy of dendritic cell vaccine against breast cancer.
Microrna-155
breast cancer
dendritic cell
immune therapy
vaccine
Journal
Oncoimmunology
ISSN: 2162-4011
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
2020
2020
Historique:
received:
24
04
2019
revised:
19
11
2019
accepted:
21
11
2019
entrez:
3
3
2020
pubmed:
3
3
2020
medline:
3
3
2020
Statut:
epublish
Résumé
MicroRNA 155 (miR-155) plays important roles in the regulation of the development and functions of a variety of immune cells. We previously revealed a vital role of miR-155 in regulating the function of dendritic cells (DCs) in breast cancer. miR-155 deficiency in DCs impaired their maturation, migration, cytokine production, and ability to activate T cells. In the current study, to exploit the therapeutic value of miR-155 for breast cancer, we examined the impact of overexpression of miR-155 on antitumor responses generated by DC vaccines. We boosted miR-155 expression in DCs by generating a miR-155 transgenic mouse strain (miR-155tg) or using lentivirus transduction. DCs overexpressing miR-155 exhibited enhanced functions in response to tumor antigens. Using miR-155 overexpressing DCs, we generated a DC vaccine and found that the vaccine resulted in enhanced antitumor immunity against established breast cancers in mice, demonstrated by increased effector T cells in the mice, suppressed tumor growth, and drastically reduced lung metastasis. Our current study suggests that in future DC vaccine development for breast cancer or other solid tumors, introducing forced miR155 overexpression in DCs via various approaches such as viral transduction or nanoparticle delivery, as well as including other adjuvant agents such as TLR ligands or immune stimulating cytokines, may unleash the full therapeutic potential of the DC vaccines.
Identifiants
pubmed: 32117588
doi: 10.1080/2162402X.2020.1724761
pii: 1724761
pmc: PMC7028336
doi:
Substances chimiques
Cancer Vaccines
0
MIRN155 microRNA, human
0
MicroRNAs
0
Mirn155 microRNA, mouse
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
1724761Subventions
Organisme : NCCIH NIH HHS
ID : P01 AT003961
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA218578
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA216230
Pays : United States
Informations de copyright
© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.
Références
Immunology. 2014 Nov;143(3):478-89
pubmed: 24891206
Invest Ophthalmol Vis Sci. 2013 Jun 10;54(6):4017-25
pubmed: 23674757
Blood. 2011 Apr 28;117(17):4490-500
pubmed: 21385848
J Immunol. 2013 Feb 1;190(3):1210-6
pubmed: 23275599
J Virol. 2013 Feb;87(4):2348-51
pubmed: 23221547
Blood. 2012 Apr 12;119(15):3478-85
pubmed: 22378844
J Immunol. 2014 Feb 1;192(3):1034-43
pubmed: 24391219
Oncoimmunology. 2016 Sep 9;5(11):e1232223
pubmed: 27999745
Arterioscler Thromb Vasc Biol. 2014 Apr;34(4):759-67
pubmed: 24504735
PLoS One. 2012;7(10):e46082
pubmed: 23091595
Oncoimmunology. 2013 Oct 1;2(10):e25771
pubmed: 24286020
Trends Immunol. 2016 Dec;37(12):855-865
pubmed: 27793569
Immunity. 2007 Dec;27(6):847-59
pubmed: 18055230
Breast Cancer Res Treat. 2014 Nov;148(2):291-302
pubmed: 25311112
Cancer Res. 2004 Jul 15;64(14):4973-9
pubmed: 15256471
Blood. 2013 Jul 11;122(2):243-52
pubmed: 23487026
Blood. 2011 Apr 21;117(16):4293-303
pubmed: 21355095
Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9482-7
pubmed: 9689106
Circulation. 2011 Jul 26;124(4):454-64
pubmed: 21730304
Immunity. 2013 Apr 18;38(4):742-53
pubmed: 23601686
Science. 2007 Apr 27;316(5824):604-8
pubmed: 17463289
Nat Med. 1995 Dec;1(12):1297-302
pubmed: 7489412
J Immunother. 2005 Sep-Oct;28(5):496-504
pubmed: 16113606
Cancer Res. 2015 Feb 1;75(3):519-31
pubmed: 25502838
J Exp Med. 1996 Jan 1;183(1):317-22
pubmed: 8551239
Nat Rev Immunol. 2008 May;8(5):362-71
pubmed: 18379575
Science. 2007 Apr 27;316(5824):608-11
pubmed: 17463290
Cancer Immunol Immunother. 2007 Nov;56(11):1817-29
pubmed: 17443323
Clin Cancer Res. 2003 Nov 1;9(14):5091-100
pubmed: 14613986
Transl Oncol. 2018 Apr;11(2):311-329
pubmed: 29413765
Cancer Res. 2001 Sep 1;61(17):6451-8
pubmed: 11522640
J Immunol. 2014 Aug 15;193(4):1690-700
pubmed: 25009204
Nat Rev Cancer. 2014 Feb;14(2):135-46
pubmed: 24457417
Int J Cancer. 2015 Mar 15;136(6):E602-13
pubmed: 25143000
Nat Immunol. 2013 Jun;14(6):593-602
pubmed: 23603793
Immunity. 2010 Oct 29;33(4):607-19
pubmed: 20888269
J Exp Med. 2002 May 20;195(10):1279-88
pubmed: 12021308